A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation-Reference-Cited by-同舟云学术

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

Published:2015-01-08 Issue:1 Volume:169 Page:36-43
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Girnius Saulius K.¹²,Lee Saem¹³⁴,Kambhampati Suman⁵,Rose Michal G.⁶,Mohiuddin Abid⁷⁸,Houranieh Antoun¹,Zimelman Abraham¹,Grady Terrence⁸,Mehta Paulette⁹,Behler Caroline¹⁰,Hayes Teresa G.¹¹,Efebera Yvonne A.¹¹²,Prabhala Rao H.¹⁴¹³,Han Andrew¹⁴,Yellapragada Sarvari V.¹¹,Klein Catherine E.¹⁴,Roodman Garson D.¹⁵¹⁶,Lichtenstein Alan¹⁷,Munshi Nikhil C.¹⁴¹³

Affiliation:

1. VA Boston Healthcare System; Boston MA USA

2. University of Cincinnati College of Medicine; Cincinnati OH USA

3. Boston University School of Medicine; Boston MA USA

4. Dana-Farber Cancer Institute; Boston MA USA

5. Kansas City Veterans Affairs Medical Center; Kansas City MO USA

6. VA Connecticut Healthcare System; West Haven CT USA

7. Atlanta VA Medical Center; Decatur GA USA

8. James A. Haley Veterans' Hospital; Tampa FL USA

9. Central Arkansas Veterans Healthcare System John L. McClellan Memorial Veterans Hospital; Little Rock AR USA

10. San Francisco VA Medical Center; San Francisco CA USA

11. Michael E. DeBakey VA Medical Center and Baylor College of Medicine; Houston TX USA

12. James Cancer Hospital at The Ohio State University Medical Center; Columbus OH USA

13. Harvard Medical School; Boston MA USA

14. VA Eastern Colorado Health Care System; Denver CO USA

15. VA Pittsburgh Healthcare System and University of Pittsburgh Medical Center; Pittsburgh PA USA

16. Indiana University School of Medicine; Indianapolis IN USA

17. VA Greater Los Angeles Healthcare System; Los Angeles CA USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13243/fullpdf

Reference20 articles.

1. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature;Argyriou;Blood,2008

2. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients;Bringhen;Blood,2010

3. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma;Dimopoulos;Leukemia,2013

4. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

5. International staging system for multiple myeloma;Greipp;Journal of Clinical Oncology,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors;Cancers;2021-06-20

2. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice;European Journal of Haematology;2018-09-05

3. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial;British Journal of Haematology;2018-05-17

4. Treatment of Patients in First or Second Relapse;Personalized Therapy for Multiple Myeloma;2017-11-01

5. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma;Singapore Medical Journal;2017-02